Using Electricity, Not Heat, to Ablate Tumors and Reinvigorate the Immune System
Using pulsed electric field ablation for resectable tumors helps not only kill the cancerous cells but might reinvigorate a patient’s immune system to fight back against their cancers.
Clinical Scorecard: Using Electricity, Not Heat, to Ablate Tumors and Reinvigorate the Immune System
At a Glance
Category Detail
Condition Resectable tumors Key Mechanisms Pulsed electric field ablation induces non-thermal cell death and stimulates immune response. Target Population Patients with resectable tumors or advanced metastatic disease. Care Setting Outpatient procedure, performed under general anesthesia.
Key Highlights
Pulsed electric field ablation is FDA approved for various tumors. Procedure can be performed bronchoscopically or percutaneously. Patients typically recover quickly and can go home the same day. Non-thermal approach reduces risks associated with traditional thermal ablation. Potential to generate systemic immune responses against tumors. Guideline-Based Recommendations
Diagnosis
Use imaging techniques for accurate tumor localization. Management
Consider pulsed electric field ablation for patients with resectable tumors. Monitoring & Follow-up
Assess recovery and monitor for any adverse effects post-procedure. Risks
Reduced risk of injury to surrounding structures due to non-thermal nature. Patient & Prescribing Data
Patients with tumors near critical structures or those with metastatic disease.
Effective for creating systemic immune responses and can be combined with other therapies.
Clinical Best Practices
Utilize imaging guidance for precise needle placement. Ensure patient sedation and comfort during the procedure. Educate patients on expected recovery and post-procedure care. References
